
PHR
Phreesia Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
27.040
Open
26.540
VWAP
26.82
Vol
394.39K
Mkt Cap
1.59B
Low
26.540
Amount
10.58M
EV/EBITDA(TTM)
--
Total Shares
57.40M
EV
1.44B
EV/OCF(TTM)
30.03
P/S(TTM)
3.41
Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q3
FY2026Q4
116.39M
+13.98%
--
--
120.69M
+13.01%
--
--
123.32M
+12.43%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for Phreesia, Inc. (PHR) for FY2026, with the revenue forecasts being adjusted by 0.18% over the past three months. During the same period, the stock price has changed by 10.84%.
Revenue Estimates for FY2026
Revise Upward

+0.18%
In Past 3 Month
Stock Price
Go Up

+10.84%
In Past 3 Month
11 Analyst Rating

18.02% Upside
Wall Street analysts forecast PHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHR is 31.63 USD with a low forecast of 28.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
0 Hold
0 Sell
Strong Buy

18.02% Upside
Current: 26.800

Low
28.00
Averages
31.63
High
35.00

18.02% Upside
Current: 26.800

Low
28.00
Averages
31.63
High
35.00
Canaccord
Buy
downgrade
$35 -> $34
2025-05-29
Reason
Canaccord
Price Target
$35 -> $34
2025-05-29
downgrade
Buy
Reason
Canaccord lowered the firm's price target on Phreesia to $34 from $35 and keeps a Buy rating on the shares. The firm noted the shares pulled back following Q1 results on revenue noise but believes the power of Phreesia's model to drive respectable growth and strong profitability is proving out. According to management the revenue noise this appears to be more isolated to timing of campaigns and not any meaningful change in Life Sciences demand.
Truist
Buy
maintain
$34 -> $35
2025-05-29
Reason
Truist
Price Target
$34 -> $35
2025-05-29
maintain
Buy
Reason
Truist raised the firm's price target on Phreesia to $35 from $34 and keeps a Buy rating on the shares. The firm cites the company's better than expected Q1 adjusted EBITDA and commentary that a big chunk of its Network Solutions revenue is locked in for the full year, with Phreesia controlling the pace of program rollouts to meet both internal and external expectations, the analyst tells investors in a research note.
Citi
Daniel Grosslight
Buy
maintain
$35 -> $33
2025-05-28
Reason
Citi
Daniel Grosslight
Price Target
$35 -> $33
2025-05-28
maintain
Buy
Reason
Keybanc
Scott Schoenhaus
Buy
Maintains
$30 → $28
2025-04-16
Reason
Keybanc
Scott Schoenhaus
Price Target
$30 → $28
2025-04-16
Maintains
Buy
Reason
KeyBanc lowered the firm's price target on Phreesia to $28 from $30 and keeps an Overweight rating on the shares. Into Q1 earnings, the firm believes the focus for the HCIT sector will be on legislative policies, healthcare system utilization, and macro concerns on a slowing economy paired with potentially higher inflation. While valuations in HCIT land remain discounted vs. healthcare more broadly, KeyBanc thinks investors should be focused on companies that can drive meet/beats over the next 12 months. Specifically, it sees the least risk from a revenue and earnings perspective from companies that are well positioned in the more stable healthcare end markets serving the payers and large pharma.
DA Davidson
Robert Simmons
Strong Buy
Maintains
$36 → $34
2025-04-14
Reason
DA Davidson
Robert Simmons
Price Target
$36 → $34
2025-04-14
Maintains
Strong Buy
Reason
DA Davidson lowered the firm's price target on Phreesia to $34 from $36 and keeps a Buy rating on the shares as part of a broader research note updating estimates within the firm's coverage of the Software group. The firm is now assuming a base case of one or two quarters of negative GDP in the US this year, which will translate to lower growth and has already translated to lower valuations, the analyst tells investors in a research note. DA Davidson adds that regardless of how the current tariff regime plays out, it sees a slowdown in consumer activity and corporate investment, at least for the next couple of quarters.
Canaccord Genuity
Richard Close
Strong Buy
Maintains
$34 → $35
2025-03-13
Reason
Canaccord Genuity
Richard Close
Price Target
$34 → $35
2025-03-13
Maintains
Strong Buy
Reason
Canaccord raised the firm's price target on Phreesia to $35 from $34 and keeps a Buy rating on the shares. The firm said they remain buyers of the shares onthe Q4 report as they believe Phreesia is a stock to own given its durable revenue, expanding margins, and improving CF profile.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Phreesia Inc (PHR.N) is -472.42, compared to its 5-year average forward P/E of -48.55. For a more detailed relative valuation and DCF analysis to assess Phreesia Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-48.55
Current PE
-472.42
Overvalued PE
59.32
Undervalued PE
-156.43
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-29.12
Current EV/EBITDA
16.37
Overvalued EV/EBITDA
109.90
Undervalued EV/EBITDA
-168.14
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair
5Y Average PS
6.34
Current PS
3.23
Overvalued PS
10.77
Undervalued PS
1.91
Financials
Annual
Quarterly
FY2026Q1
YoY :
+14.54%
115.94M
Total Revenue
FY2026Q1
YoY :
-83.07%
-3.29M
Operating Profit
FY2026Q1
YoY :
-80.15%
-3.91M
Net Income after Tax
FY2026Q1
YoY :
-80.00%
-0.07
EPS - Diluted
FY2026Q1
YoY :
-220.93%
7.46M
Free Cash Flow
FY2026Q1
YoY :
+2.39%
61.23
Gross Profit Margin - %
FY2026Q1
YoY :
-142.89%
5.04
FCF Margin - %
FY2026Q1
YoY :
-82.65%
-3.38
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
1.6M
USD
20
3-6
Months
4.0M
USD
37
6-9
Months
6.7M
USD
41
0-12
Months
1.1M
USD
22
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
2
554.0K
Volume
Months
6-9
3
1.8M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
1.6M
USD
20
3-6
Months
4.0M
USD
37
6-9
Months
6.7M
USD
41
0-12
Months
1.1M
USD
22
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
PHR News & Events
Events Timeline
2025-05-28 (ET)
2025-05-28
07:10:33
Phreesia backs FY26 revenue view $472M-$482M, consensus $475.57M

2025-05-28
07:08:48
Phreesia reports Q1 EPS (7c), consensus 16c

2025-03-12 (ET)
2025-03-12
16:07:32
Phreesia backs FY26 revenue view $472M-$482M, consensus $476.6M

Sign Up For More Events
Sign Up For More Events
News
5.0
07-18NASDAQ.COMInsider Sale: Director at $PHR Sells 465 Shares
5.0
07-04NASDAQ.COMInsider Sale: Director at $PHR Sells 7,000 Shares
8.0
06-18NASDAQ.COMInteresting PHR Put Options For August 15th
Sign Up For More News
People Also Watch

TVTX
Travere Therapeutics Inc
15.660
USD
-1.01%

CSTM
Constellium SE
14.310
USD
+2.80%

VET
Vermilion Energy Inc.
8.080
USD
+4.12%

HE
Hawaiian Electric Industries Inc
10.820
USD
-0.73%

TROX
Tronox Holdings PLC
5.600
USD
+2.56%

LTC
LTC Properties Inc
35.440
USD
+0.85%

CLMT
Calumet Inc
17.020
USD
+2.90%

CLDX
Celldex Therapeutics Inc
22.360
USD
+1.36%

DMLP
Dorchester Minerals LP
27.120
USD
-0.26%

MAG
MAG Silver Corp
22.150
USD
+1.84%
FAQ

What is Phreesia Inc (PHR) stock price today?
The current price of PHR is 26.8 USD — it has increased 0.94 % in the last trading day.

What is Phreesia Inc (PHR)'s business?

What is the price predicton of PHR Stock?

What is Phreesia Inc (PHR)'s revenue for the last quarter?

What is Phreesia Inc (PHR)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Phreesia Inc (PHR)'s fundamentals?

How many employees does Phreesia Inc (PHR). have?
